Industry News

Bayer among financial backers of startup Century Therapeutics’ cell-based immunotherapy platform

July 7, 2019
Bayer has invested $215 million in Century Therapeutics, a biotech startup looking to break into the oncology cell therapy market with a platform…

Therapeutic vaccine could improve checkpoint blockade efficacy for patients with cancer

July 3, 2019
Researchers at Icahn School of Medicine at Mount Sinai have developed a novel vaccine that uses immune stimulants to inhibit cancer cell growth among…

City of Hope appoints hematologists to new roles

July 3, 2019
Two hematologists at City of Hope have been appointed to new positions. Larry Kwak, MD, PhD, has been named deputy director of City of…

OncoSec, Dana-Farber strike exclusive rights agreement for CAR T-cell technology

June 30, 2019
OncoSec Medical has announced a collaborative agreement with Dana-Farber Cancer Institute for the development of chimeric antigen receptor T-cell…

Meeting News

Investigational CAR T-cell therapy induces durable responses in pretreated leukemia subtypes

June 24, 2019
CHICAGO — Heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and prior ibrutinib treatment achieved…

FDA News

Cell therapy receives orphan drug designation for chronic heart failure

June 24, 2019
The FDA granted orphan drug designation to rexlemestrocel-L for the prevention of postimplantation mucosal bleeding in patients with end-stage…

8 important updates for Cancer Immunotherapy Month

June 22, 2019
Cancer Immunotherapy Month is observed every June. The initiative — organized by Cancer Research Institute — is designed to increase…

FDA News

FDA grants fast track designation to TRQ-1501 T-cell therapy for solid tumors, lymphoma

June 18, 2019
The FDA granted fast track designation to TRQ-1501, a deep-primed IL-15 T-cell immunotherapy for the treatment of relapsed or refractory solid tumors…

Meeting News

Claudin-specific CAR T cells safe, effective in advanced gastric, pancreatic adenocarcinoma

June 17, 2019
CHICAGO — One-third of a small cohort of patients with advanced gastric or pancreatic adenocarcinoma achieved objective responses to treatment…

Meeting News

MD Anderson releases free CAR T-cell therapy toxicity grading and management app

June 7, 2019
CHICAGO — The University of Texas MD Anderson Cancer Center has developed a new mobile app that assists with the grading and management of…

Meeting NewsPerspective

Point-of-care bispecific targeting ‘offers new paradigm’ for CAR T-cell therapy

June 4, 2019
CHICAGO — A novel bispecific anti-CD19 and anti-CD20 chimeric antigen receptor T-cell therapy has shown promising overall response rates for…

Meeting NewsPerspective

Bispecific T-cell engager AMG 420 active, safe in heavily pretreated multiple myeloma

June 3, 2019
CHICAGO — The investigational drug AMG 420 induced encouraging clinical responses among patients with relapsed or refractory multiple myeloma…

Meeting NewsPerspective

Tumor-infiltrating lymphocyte therapy appears safe, effective in melanoma, cervical cancer

June 2, 2019
CHICAGO — Data from two trials evaluating the safety and efficacy of adoptive cell transfer with autologous tumor-infiltrating lymphocytes…

Meeting News

High-intensity bridging therapy before CAR T-cell infusion does not improve outcomes in leukemia subset

June 1, 2019
CHICAGO — Patients who received high-intensity bridging chemotherapy before CD19 chimeric androgen receptor T-cell therapy for relapsed or…

Meeting News

CAR T-cell therapy total cost can exceed $1.5 million per treatment

May 29, 2019
PHILADELPHIA — When factoring in all the costs associated with chimeric antigen receptor T-cell therapy, hospitals may charge as much as $1.5…

Trend Watch

UCLA Researchers Awarded $4.6m for Stem Cell Immunotherapy Trial

Cell Therapy Next, May 2019
The California Institute for Regenerative Medicine has awarded a $4.6 million grant for a phase 1 clinical trial of a new modified blood-forming stem…

Clinical Trials Snapshot

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Cell Therapy Next, May 2019
Phase 1/2 dose-escalation trial to determine the safety and efficacy of chimeric antigen receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-transduced…

In the JournalsPerspective

New CAR T-cell Therapy Shows No Severe Toxic Side Effects

Cell Therapy Next, May 2019
A novel version of CAR T-cell therapy has shown no severe toxic side effects in patients with recurrent lymphoma, according to a study published in…

The Handoff: Transferring CAR T Patients Back to the Community Setting

Cell Therapy Next, May 2019
Julio C. Chavez, MD
In this installment of In Practice, Julio C. Chavez, MD, assistant member in the lymphoma section of the department of malignant hematology at…

Clinical Trials Snapshot

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Interleukin-2

Cell Therapy Next, May 2019
Phase I trial to determine the maximum tolerated/maximum feasible dose of a single infusion of FATE-NK100 via intra-peritoneal catheter in women with…